Breakthrough in Schizophrenia Treatment

A groundbreaking digital therapeutic has just shown remarkable promise in a phase 3 trial aimed at alleviating the negative symptoms of schizophrenia. Developed by Boehringer Ingelheim in partnership with Click Therapeutics, the investigational therapy, known as CT-155, is designed to complement traditional antipsychotic drugs, targeting the often-debilitating negative symptoms experienced by many patients.

A Global Crisis Affecting Millions

Schizophrenia is a severe mental health disorder affecting approximately 24 million individuals globally, according to the World Health Organization. Patients frequently endure persistent delusions and hallucinations, but the challenges go deeper: around 60% also grapple with negative symptoms, including a diminished capacity to feel pleasure, flat affect, communication issues, and lack of motivation.

Current Treatments Fall Short

Sadly, existing medications do little to address these negative symptoms, which can severely hinder day-to-day functioning. Enter CT-155, a innovative smartphone app that leverages cutting-edge AI technology to engage patients and support them in symptom management. Notably, it received breakthrough device designation in January 2024, marking it as a significant advancement in treatment options.

Voices of Experts

Dr. Emmanuelle Clerisme-Beaty, Medical Director at Boehringer Ingelheim, highlighted the urgent need for effective treatments: Despite the availability of various treatments, no approved options exist for the negative symptoms of schizophrenia in the U.S. This represents a critical gap in care for these patients and their loved ones.

Promising Results from the CONVOKE Study

The recent CONVOKE study tested CT-155 against a digital control app while being paired with standard antipsychotic therapy. Involving 464 stable patients, the trial confirmed that CT-155 was not only well tolerated but also produced safe and effective results, surpassing primary endpoints in improving negative symptoms of schizophrenia as per the Clinical Assessment Interview for Negative Symptoms.

What’s Next for CT-155?

Detailed findings from this study will be unveiled at the Novel Therapeutics Symposium on October 13, 2025, as part of the prestigious 38th Annual ECNP Congress in Amsterdam. As interest in digital therapies surges, the collaboration between Click Therapeutics and Boehringer Ingelheim is set to expand, promising even more options for patients struggling with schizophrenia.

Beyond Schizophrenia: A Broader Impact

Click Therapeutics isn’t stopping at CT-155; it has received approval for several other prescription digital products. Earlier this year, they launched Rejoyn (formerly CT-152), an adjunctive therapy for major depressive disorder priced at $200 for a comprehensive six-week program, enhancing emotional control through specialized cognitive training.